Steven J Cohen Selected Research

Esophageal Neoplasms (Esophageal Cancer)

1/2023	Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.
8/2017	Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
11/2016	Risk of radiation pneumonitis in patients receiving taxane-based trimodality therapy for locally advanced esophageal cancer.
1/2016	Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer.
11/2015	Association of treatment factors with surgical outcomes in tri-modality therapy for esophageal cancer.
1/2015	Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.
12/2012	The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
7/2012	Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.
5/2011	Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer.
7/2009	Influence of Diabetes on the Interpretation of PET Scans in Patients With Esophageal Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steven J Cohen Research Topics

Disease

47	Neoplasms (Cancer) 01/2023 - 07/2002
27	Adenocarcinoma 01/2023 - 04/2003
26	Pancreatic Neoplasms (Pancreatic Cancer) 09/2022 - 01/2002
18	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 08/2005
10	Esophageal Neoplasms (Esophageal Cancer) 01/2023 - 07/2009
8	Carcinoma (Carcinomatosis) 01/2021 - 10/2007
6	Neoplasm Metastasis (Metastasis) 01/2017 - 07/2005
6	Rectal Neoplasms (Rectal Cancer) 01/2016 - 12/2005
3	Vomiting 10/2020 - 04/2003
3	Neutropenia 01/2019 - 04/2003
3	Pathologic Complete Response 06/2015 - 10/2007
3	Diarrhea 02/2008 - 07/2002
2	Colonic Neoplasms (Colon Cancer) 10/2021 - 06/2015
2	Exanthema (Rash) 10/2020 - 04/2003
2	Nausea 10/2020 - 04/2003
2	Cardiotoxicity 10/2013 - 07/2012
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2011 - 03/2011
2	Circulating Neoplastic Cells 10/2007 - 07/2006
2	Fatigue 06/2004 - 04/2003
1	Margins of Excision 01/2022
1	Lymphatic Metastasis 10/2021
1	Obesity 01/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Hyperlipidemias (Hyperlipidemia) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Cachexia 01/2019
1	Inflammation (Inflammations) 01/2019
1	Radiation Pneumonitis 11/2016

Drug/Important Bio-Agent (IBA)

10	Gemcitabine FDA Link 10/2020 - 07/2010
8	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2016 - 07/2005
6	Capecitabine (Xeloda)FDA Link 01/2021 - 02/2008
6	Fluorouracil (Carac)FDA LinkGeneric 08/2017 - 07/2002
5	130-nm albumin-bound paclitaxelIBA 01/2023 - 04/2016
5	Irinotecan (Camptosar)FDA LinkGeneric 10/2017 - 06/2004
5	Bevacizumab (Avastin)FDA Link 01/2017 - 02/2011
5	ErbB Receptors (EGF Receptor)IBA 09/2014 - 08/2005
4	Leucovorin (Folinic Acid)FDA Link 10/2016 - 06/2012
3	EnzymesIBA 01/2021 - 04/2003
3	MucinsIBA 09/2015 - 03/2009
3	Proteins (Proteins, Gene)FDA Link 08/2008 - 04/2003
2	PlatinumIBA 01/2023 - 01/2020
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 08/2017
2	AlbuminsIBA 01/2021 - 04/2015
2	Hemoglobins (Hemoglobin)IBA 01/2021 - 02/2017
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2020 - 04/2015
2	4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- oneIBA 01/2018 - 07/2010
2	Carcinoembryonic AntigenIBA 10/2017 - 01/2017
2	Cell Adhesion MoleculesIBA 10/2017 - 03/2009
2	YttriumIBA 01/2017 - 09/2015
2	Cetuximab (Erbitux)FDA Link 10/2016 - 12/2012
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2016 - 10/2014
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 09/2015 - 06/2011
2	Proteasome InhibitorsIBA 06/2014 - 02/2008
2	Bortezomib (Velcade)FDA Link 06/2014 - 02/2008
2	Monoclonal AntibodiesIBA 04/2014 - 12/2010
2	Insulin (Novolin)FDA Link 10/2013 - 07/2009
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2012 - 02/2011
2	Peptides (Polypeptides)IBA 12/2011 - 03/2011
2	Biomarkers (Surrogate Marker)IBA 02/2011 - 03/2009
2	Glucose (Dextrose)FDA LinkGeneric 07/2009 - 05/2009
2	tipifarnib (R115777)IBA 06/2004 - 04/2003
2	Farnesyltranstransferase (Farnesyltransferase)IBA 06/2004 - 04/2003
1	cixutumumabIBA 01/2023
1	folfirinoxIBA 01/2023
1	regorafenibIBA 10/2022
1	Tyrosine Kinase InhibitorsIBA 10/2022
1	cabozantinibIBA 10/2022
1	hydroxide ionIBA 10/2021
1	AdiponectinIBA 10/2021
1	Vitamin D FDA LinkGeneric 10/2021
1	25-hydroxyvitamin DIBA 10/2021
1	thiamine triphosphorate (TTP)IBA 01/2021
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2021
1	Quinacrine (Mepacrine)IBA 01/2021
1	Recombinant Fusion ProteinsIBA 10/2020
1	pembrolizumabIBA 01/2020
1	itacitinibIBA 01/2019
1	IsoenzymesIBA 01/2019
1	CytokinesIBA 01/2019
1	trifluridine tipiracil drug combinationIBA 12/2018
1	labetuzumab govitecanIBA 10/2017
1	Immunoconjugates (Immunoconjugate)IBA 10/2017
1	vandetanib (ZD6474)IBA 08/2017
1	Carboplatin (JM8)FDA LinkGeneric 08/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	taxaneIBA 11/2016

Therapy/Procedure

40	Therapeutics 01/2023 - 01/2002
23	Drug Therapy (Chemotherapy) 01/2023 - 11/2007
12	Radiotherapy 01/2018 - 08/2005
8	Neoadjuvant Therapy 01/2022 - 12/2005
5	Chemoradiotherapy 12/2012 - 10/2007
3	Esophagectomy 01/2016 - 12/2012
3	Pancreatectomy 12/2011 - 05/2008
2	Combination Drug Therapy (Combination Chemotherapy) 01/2020 - 06/2012
2	Microspheres (Microsphere) 12/2015 - 04/2015
2	Radioimmunotherapy 09/2015 - 06/2011
1	Palliative Care (Palliative Therapy) 09/2022
1	Adjuvant Chemotherapy 10/2021
1	Length of Stay 01/2021
1	Pancreaticoduodenectomy 01/2021